Compare Biogen Inc (BIIB) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs JPMorgan Chase & Co — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while JPMorgan Chase & Co trades at $344.69 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 32.2× Biogen Inc's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | JPM | |
|---|---|---|
Market Cap | $28.34B | $911.47B |
Sector | Health | Financials |
52-Week High | $216.63 | $342.89 |
52-Week Low | $122.68 | $282.84 |
Enterprise Value | $30.62B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with $181.85B revenue in 2025 and net income of $57.05B, though recent earnings were mixed with a Q4 2025 miss but Q1 and Q2 2026 beats. Analyst consensus is moderately bullish with a $369.67 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
JPMorgan presents a solid investment case with robust profitability (31.61% net margin, 17.03% ROE) and reasonable valuation (P/E 14.69). Risks include geopolitical tensions impacting banking operations and cybersecurity threats from advanced AI. The stock offers upside to analyst targets but faces headwinds from economic uncertainty and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
